- $332.28m
- -$18.64m
- $1.08m
- 39
- 19
- 14
- 12
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 0.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 309.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.22% | ||
| Return on Equity | -37.62% | ||
| Operating Margin | -7518.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.15 | 1.07 | 0.35 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 5th, 2019
- Public Since
- October 25th, 2024
- No. of Shareholders
- 103
- No. of Employees
- 75
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 44,422,505
- Address
- 250 East Grand Avenue, Suite 65, SOUTH SAN FRANCISCO, 94080
- Web
- https://septerna.com/
- Phone
- +1 6503383533
- Auditors
- Ernst & Young LLP
Upcoming Events for SEPN
Similar to SEPN
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Septerna share price?
As of Today at 23:10 UTC, shares in Septerna are trading at $7.48. This share price information is delayed by 15 minutes.
How has the Septerna share price performed this year?
Shares in Septerna last closed at $7.48 and the price had moved by over the past 365 days. In terms of relative price strength the Septerna share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Septerna?
The overall consensus recommendation for Septerna is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Septerna dividend yield?
Septerna does not currently pay a dividend.
Does Septerna pay a dividend?
Septerna does not currently pay a dividend.
When does Septerna next pay dividends?
Septerna does not currently pay a dividend.
How do I buy Septerna shares?
To buy shares in Septerna you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Septerna?
As of the previous close price of $7.48, shares in Septerna had a market capitalisation of $332.28m.
Where are Septerna shares listed?
Here are the trading details for Septerna:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SEPN
What kind of share is Septerna?
Based on an overall assessment of its quality, value and momentum Septerna is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Septerna share price forecast for 2025?
The analyst consensus target price for shares in Septerna is $15.50. That is 107.22% above the last closing price of $7.48.
Analysts covering Septerna currently have a consensus Earnings Per Share (EPS) forecast of -$1.88 for the next financial year.
Find out moreWhat is the trend in the Septerna share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Septerna. Over the past six months, its share price has underperformed the S&P500 Index by -65.52%.
As of the last closing price of $7.48, shares in Septerna were trading -49.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Septerna PE Ratio?
The Septerna PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Septerna?
We do not have data on Septerna's directors